Reduced expression of arginosuccinate synthase 1 (ASS1) has been observed in melanoma, glioma, lymphoma, and prostate cancer (78), and arginine deprivation therapy may generate antitumor efficacy in these cancer cells due to ASS1-involved arginine synthesis. The gene discussed is ASS1; the disease is prostate carcinoma.